Navigation Links
Sinovac Closes $9.75 Million Private Placement
Date:2/4/2008

BEIJING, Feb. 4 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a leading provider of vaccines in China, today announced the completion of a $9.75 million private placement of its common shares.

On January 22, 2008, Sinovac entered into a share purchase agreement with Sansar Capital Management, L.L.C. The private placement with Sansar closed on February 1, 2008. Sinovac received approximately $9.75 million in gross proceeds from the sale of 2,500,000 of its common shares at a purchase price of $3.90 per share. Sinovac plans to use the funds for general corporate purposes and working capital, including acquisition opportunities that may arise from time to time.

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an applicable exemption from the registration requirements.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's vaccines include Healive(TM) (hepatitis A), Bilive(TM) (combined hepatitis A and B) and Anflu(TM) (influenza). Sinovac is currently developing human vaccines against the H5N1 strain of pandemic influenza, and Japanese encephalitis. Additional information about Sinovac is available on its website, http://www.sinovac.com. To be added to our distri
'/>"/>

SOURCE Sinovac Biotech Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sinovac Announces Postponement of Annual General Meeting
2. Sinovac Requests Extension for Annual Shareholders Meeting
3. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
4. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
5. Genmab Discloses Target and Development Plans for HuMax-Inflam
6. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
7. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
8. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
9. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
10. BioVex Closes Second Round of Series E Financing
11. Pharmaxis Closes Share Purchase Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... According to new market research report "Data ... Enterprise, Telecom), by Design Types (Electrical, Mechanical), and ... 3, Tier 4) - Global Forecast to 2019", ... Center Construction Market into various segments with an ... report also identifies the factors driving this market, ...
(Date:10/25/2014)... SonaCare Medical, LLC, leader in ... announced that its Board of Directors has appointed ... President and member of the Board effective immediately. ... expanded responsibilities within the company, including further developing ... commercialization, manufacturing and finance. , Dr. Carol ...
(Date:10/25/2014)... -- RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX) ("the Company" or "RegeneRx") ... Symposium on Thymosins in Health and Disease in ... thymosin beta 4 (TB4) linked with rhodamine (a fluorescent ... a rodent model of stroke, it was visualized outside ... functional tissue of the brain).   The leakage of TB4 ...
(Date:10/22/2014)... -- Research and Markets has announced ... Market (Product types, Application, Technology, End User and ... Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and ... offering. This new report titled, ... and Geography) Global Size, Industry Analysis, Trends, Opportunities, ...
Breaking Biology Technology:Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 2SonaCare Medical Board of Directors Appoints Dr. Mark Carol as CEO and President 3Researchers Report Thymosin Beta 4 Crosses Blood-Brain Barrier In Animal Stroke Model 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3
... and biochemistry at The University of Texas at Austin, ... with Professor William Moerner of Stanford University. , The ... Tamir, was given to the two scientists for their ... and imaging. , The $100,000 prize will be presented ...
... service revenue of $238.7 million grows 32% year-over-year, - Operating ... - Backlog increases 41% ... - Net quarterly book-to-burn ratio equates ... PRXL ) today announced its financial results for the,second quarter ended ...
... of Family Cord Blood Banks, LOS ANGELES, ... of California Cryobank, today announced that its co-founder ... appointed to the Department,of Health and Human Services, ... on Blood Stem Cell Transplantation,(ACBSCT). Through his appointment, ...
Cached Biology Technology:PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 2PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 3PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 4PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 5PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 6PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 7PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 8PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 9PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results 10Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 2Dr. Charles A. Sims of California Cryobank's Family Cord Blood Services Named to National Stem Cell Advisory Council 3
(Date:10/18/2014)... patients referred for evaluation of suspected genetic conditions, ... 25 percent, including detection of a number of ... disease, according to a study appearing in ... coincide with the American Society of Human Genetics ... or coding regions of thousands of genes simultaneously ...
(Date:10/17/2014)... is available in German . ... sperms every day in order to reproduce? And why are ... topic of the latest issue of the research journal ... evolutionary biologist Steven Ramm from Bielefeld University Bielefeld has compiled ... not unusual for a female to copulate with several males ...
(Date:10/16/2014)... war on the human body. Battles are won, ... pancreatic cancer, this stalemate—known as tumor dormancy—can last ... a phenomena that is poorly understood. , ... of Salvatore Torquato, a Professor of Chemistry at ... tumor dormancy and the switch to a malignant ...
Breaking Biology News(10 mins):Whole-exome sequencing shows potential as diagnostic tool 2Sperm wars 2Modeling tumor dormancy 2
... A new grant from the National Institute of Biomedical ... of Health (NIH), will provide funding for University of ... novel bioreactor system that will control mechano-electrochemical environment for ... properties of engineered tissues. The two-year, $735,000 grant will ...
... Il. A key statistic that consumer groups and ... national rankings can be misleading, researchers report in a new ... number above 1.0 indicates a hospital had more deaths than ... were fewer than the expected number of deaths. The ...
... Aquaculture, once a fledgling industry, now accounts for 50 percent ... by an international team of researchers. And while the industry ... significant strain on marine resources by consuming large amounts of ... authors conclude. Their findings are published in the Sept. 7 ...
Cached Biology News:University of Miami receives NIH grant to support novel technology for tissue engineering 2Treating bone loss in breast cancer survivors 2Half of the fish consumed globally is now raised on farms, study finds 2Half of the fish consumed globally is now raised on farms, study finds 3
ANTI GELSOLIN...
...
... is intended for the derivation of ... in serum-free conditions. ... Clonal Grade Medium Basal Medium ... Trypsin Solution Gelatin Solution Complete Freezing ...
Template and primers for preparation of internal control spots...
Biology Products: